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Background: Long noncoding RNAs (lncRNAs) are an emerging class of relatively
underexplored oncogenic molecules with biological and clinical significance. Current
inadequacies for stratifying patients with aggressive disease presents a strong rationale
to systematically identify lncRNAs as clinical predictors in localized prostate cancer.
Objective: To identify RNA biomarkers associated with aggressive prostate cancer.
Design, setting, and participants: Radical prostatectomy microarray and clinical data
was obtained from 910 patients in three published institutional cohorts: Mayo Clinic I
(N = 545, median follow-up 13.8 yr), Mayo Clinic II (N = 235, median follow-up 6.7 yr),
and Thomas Jefferson University (N = 130, median follow-up 9.6 yr).
Outcome measurements and statistical analysis: The primary clinical endpoint was
distant metastasis-free survival. Secondary endpoints include prostate cancer-speciﬁc
survival and overall survival. Univariate and multivariate Cox regression were used to
evaluate the association of lncRNA expression and these endpoints.
Results and limitations: An integrative analysis revealed Prostate Cancer Associated
Transcript-14 (PCAT-14) as the most prevalent lncRNA that is aberrantly expressed in
prostate cancer patients. Down-regulation of PCAT-14 expression signiﬁcantly associated with Gleason score and a greater probability of metastatic progression, overall
survival, and prostate cancer-speciﬁc mortality across multiple independent datasets
and ethnicities. Low PCAT-14 expression was implicated with genes involved in biological processes promoting aggressive disease. In-vitro analysis conﬁrmed that low PCAT14 expression increased migration while overexpressing PCAT-14 reduced cellular
growth, migration, and invasion.
Conclusions: We discovered that androgen-regulated PCAT-14 is overexpressed in
prostate cancer, suppresses invasive phenotypes, and lower expression is signiﬁcantly
prognostic for multiple clinical endpoints supporting its signiﬁcance for predicting
metastatic disease that could be used to improve patient management.
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Patient summary: We discovered that aberrant prostate cancer associated transcript-14
expression during prostate cancer progression is prevalent across cancer patients. Prostate
cancer associated transcript-14 is also prognostic for metastatic disease and survival
highlighting its importance for stratifying patients that could beneﬁt from treatment
intensiﬁcation.
# 2016 European Association of Urology. Published by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).

1.

Introduction

from 1010 men with high-risk prostate cancer that was enriched with all
of the remaining metastatic cases from the 80% of men not sampled

The majority of prostate cancer patients are diagnosed at a
potentially curable stage and are often treated with radical
prostatectomy or other first-line treatments [1]. However, a
subset of patients with aggressive disease face the risk of
prostate cancer recurrence, which can manifest as persistently elevated/increasing serum prostate-specific antigen
or metastasis. Therefore, a critical goal in prostate cancer
research is determining the molecular underpinnings of
aggressive and indolent disease to improve patient management and prognosis. Recent studies demonstrated the
utility of protein-coding genes as prognostic biomarkers
[2,3]. However, the lack of tissue specificity hinders the
ability to monitor their expression levels noninvasively. In
contrast, long noncoding RNAs (lncRNAs) are used successfully to diagnosis and risk stratify prostate cancer
[4,5]. Therefore, our study focuses on exploring lncRNAs
as biomarkers for risk stratification to ultimately improve
patient management.
Our group and others have leveraged next-generation
sequencing to generate an unbiased transcriptome to
discover novel lncRNAs in prostate cancer [6–8]. This has
spurred numerous studies exploring the biological and
clinical significance of lncRNAs [5,9,10]. However, to date,
all of the transcriptome-based discoveries have utilized
patient samples from high quality specimens (ie, abundance
of tissue, snap frozen tissue, recently collected), which
made them ideal to perform transcriptome sequencing but
lacked longer-term clinical outcomes. To address this, we
performed an integrative analysis of multiple independent
transcriptome data collections [7,11,12] coupled with an
unconventional microarray platform, with probe coverage
of a significant portion of lncRNAs, to associate lncRNA
expression with long-term outcomes such as metastasis,
overall survival, and prostate-cancer specific mortality.
2.

Patients and methods

2.1.

Clinical association of PCAT-14

Microarray data was obtained from four previously published datasets
from the Decipher Genomic Resource Information Database [13–16]. Data
can also be found in the Gene Expression Omnibus: GSE29079, GSE46691,
GSE62116, and GSE72291. Cancer versus normal analysis was performed
in the pooled cohorts by Brase et al [13]. Clinical endpoints were
evaluated in the Mayo Clinic I and II (MCI and II) cohorts and the Thomas
Jefferson University (TJU) cohort. The MCI cohort consisted of 545 patients
from a nested case control study with matched triplets for no recurrence,
biochemical recurrence only, and metastasis after prostatectomy. The
MCII cohort consisted of a case-cohort study with a 20% random sampling

resulting in 235 patients. Postsurgical therapies for both Mayo cohorts
were at the treating physician’s discretion. The TJU cohort consisted of
130 patients with pT3 or margin-positive disease who received
postoperative radiation therapy, with hormone therapy at the treating
physician’s discretion. PCAT-14 expression was calculated by taking the
mean expression of probe sets mapping to exons. A Student’s t-test was
used to test differences in expression between cancer and normal
samples. High/low PCAT-14 expression was determined by splitting at the
median expression level. Kaplan-Meier curves are shown and statistical
inference was performed using the Log-rank test. Addition of PCAT-14 to
Cancer of the Prostate Risk Assessment Postsurgical score (CAPRA-S)
[17,18] was obtained by training a logistic regression model with both
variables, and the model predictions were compared with CAPRA-S alone
[5]. Time-dependent receiver operating curves and the area under the
curve was calculated using the ‘‘timeROC’’ R package (by Paul Blanche).
Multivariable analysis was performed using Cox regression stratiﬁed by
cohort to adjust for baseline differences. Association of PCAT-14 with
clinicopathologic variables was performed and statistical association with
continuous variables was assessed using a Student t-test, and categorical
variables with the chi-square test. All statistical tests were two-sided and
signiﬁcance was set as p < 0.05. Our study adheres to Reporting
recommendations for tumor marker prognostic studies criteria [19].

3.

Results

3.1.

Integrative lncRNA analysis

To identify consistently altered lncRNAs during prostate
cancer progression, we performed an integrative analysis of
three patient cohorts (Supplementary Table 1): (1) transcriptome sequencing of 14 primary tumors and matched
adjacent normal tissue (Ren et al cohort) [7], (2) transcriptome sequencing of 20 primary tumors and 10 matched
adjacent normal tissues (Kannan et al cohort) [12], and (3)
Affymetrix gene expression of 131 primary and 19 metastatic tumors (Taylor et al cohort) [11]. Four lncRNAs were
up-regulated and one lncRNA was down-regulated between
the primary tumors and normal tissue across all three
cohorts (Fig. 1A, Supplementary Tables 2–5).
Leveraging the clinical data associated with the Taylor
et al cohort [11], we next assessed if the lncRNAs were
associated with aggressive disease based on Gleason score.
While multiple candidates are reported to have altered
expression in prostate tumors (ie, DRAIC [9], PCAT-14 [6],
PCAT-101 [6]), PCAT-14 was the only lncRNA significantly
down-regulated in patients with high (9) relative to low (6)
Gleason scores (p = 0.00013; Fig. 1B, Supplementary
Table 2) and negatively correlated with Gleason score
(correlation = 0.22). Confirming earlier findings [6], PCAT14 displayed altered expression throughout prostate tumor
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Fig. 1 – Integrative analysis reveals Prostate Cancer Associated Transcript-14 (PCAT-14) expression associates with prostate cancer. (A) Differentially
expressed (DE) long noncoding RNAs (lncRNAs) between normal and tumor samples of prostate cancer in one Affymetrix dataset and two RNA-seq
datasets (Supplementary Table 1). The Venn diagram shows the number of up-regulated (orange arrow) and down-regulated (blue arrow) DE lncRNAs
identified in one to three datasets. Heatmaps of the normalized Affymetrix expression and normalized RNA-seq log fragments per kilobase of exon per
million fragments mapped (FPKM) of the five DE lncRNAs from all three datasets are shown across normal, tumor, and metastatic samples in each
datasets. Four of the five DE lncRNAs are up-regulated in the tumor dataset and one is down-regulated in all three datasets. Among these five
lncRNAs, PCAT-14 is the only one that shows an association with tumor progression (Supplementary Table 2). (B) Boxplot of normalized Affymetrix
expression of PCAT-14 in Gleason 6 through 9. Expression of PCAT-14 is anticorrelated with Gleason score (correlation [cor] = S0.22). Expression of
PCAT-14 is significantly decreases from Gleason 6 to 9 (p = 0.00013). (C) Boxplot of normalized Affymetrix expression of PCAT-14 in normal, tumor, and
metastatic prostate samples. PCAT-14 is up-regulated in tumor samples compared with normal samples (p = 1.3e-15), and its expression goes down
again in metastatic patients from the tumor dataset (p = 9.7e-06).

progression (Fig. 1C, Supplementary Fig. 1) as exemplified by
PCAT-14 up-regulation in primary tumors compared with
normal tissue (p = 1.3e-15) and PCAT-14 down-regulation in
metastatic relative to primary tumors (p = 9.7e-06).
Notably, PCAT-14 expression is enriched in prostate
cancer as shown in our pan-cancer expression analysis of
6853 specimens across 18 additional solid tumors, as part of
The Cancer Genome Atlas consortium (Supplementary Fig.
2). This is further supported by a recent study reporting
PCAT-14, under the gene alias PRCAT-104, to have altered
expression specifically in prostate cancer [8]. Validation of
PCAT-14 expression in a prostate cancer cell line panel
relative to the control cell line, RWPE, confirmed overexpression of PCAT-14 in 22Rv1 and VCaP cell lines
(Supplementary Fig. 3A). Subcellular localization revealed
that PCAT-14 is enriched in the nucleus (Supplementary Fig.
3B), which is common amongst lncRNAs associated with
gene regulation.
3.2.

Clinical significance of PCAT-14

Given the altered expression of PCAT-14 in prostate cancer,
we hypothesized a potential relationship with clinical
outcomes. Therefore, we assessed PCAT-14 expression

within a cohort of 910 radical prostatectomy specimens
from three independent patient cohorts from the Decipher
Genomic Resource Information Database: MCI (N = 545),
MCII (N = 235), and TJU (N = 130). There were 298 total
metastasis events (124 in PCAT-14 high patients, 174 in
PCAT-14 low patients), 166 total deaths from prostate
cancer (69 in PCAT-14 high patients, 97 in PCAT-14 low
patients), and 366 total deaths (175 in PCAT-14 high
patients, 191 in PCAT-14 low patients) in our cohorts.
Patients with high versus low expression of PCAT-14
showed significantly different rates of distant metastasis
free
survival
(MCI:
p = 0.0024,
hazard
ration
[HR] = 0.66 [0.5–0.86], MCII: p = 0.023, HR = 0.59 [0.37–
0.94], TJU [borderline]: p = 0.093, HR = 0.33 [0.084–1.3]) in
Fig. 2A, overall survival (MCI: p = 0.0044, HR = 0.71 [0.56–
0.9], MCII: p = 0.14, HR = 0.68 [0.41–1.1], TJU: p = 0.0061,
HR = 0.35 [0.16–0.77]) in Fig. 2B, and prostate cancer
specific survival (MCI: p = 0.00059, HR = 0.54 [0.38–0.77],
MCII: p = 0.023, HR = 0.44 [0.22–0.91], TJU [unavailable]) in
Fig. 2C. Consistent with these data, lower PCAT-14 expression associated with Gleason score as well as lymph node
invasion (Table 1). The prognostic ability of PCAT-14 is
significant even after accounting for clinicopathologic
variables (age, prostate-specific antigen, Gleason, surgical
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Fig. 2 – Prostate cancer associated transcript-14 (PCAT-14) as a single gene predictor of aggressive disease. Kaplan-Meier analyses of prostate cancer
outcomes in the Mayo Clinic cohort. PCAT-14 expression was measured using Affymetrix exon arrays, and participants were stratified according to
PCAT-14 expression. Participant outcomes were analyzed for (A) distant metastasis-free survival, (B) overall survival, and (C) prostate cancer specific
survival, across three patients cohorts (from left to right) Mayo I, Mayo II, and Thomas Jefferson. The p values were calculated using a log-rank test.
The number at risk is shown at the bottom of each plot.
HR = hazard ratio.

margin status, seminal vesicle invasion, extracapsular
extension, and lymph node invasion) on a pooled multivariable cox analysis (Table 2) of these cohorts (distant
metastasis free survival: p = 0.002, HR = 0.68 [0.53–0.87],
prostate cancer specific survival: p = 0.015, HR = 0.68 [0.53–
0.87], borderline significant for overall survival: p = 0.056,
HR = 0.81 [0.65–1.01]).
Additionally, we investigated if PCAT-14 would improve
the performance of an existing prediction algorithm,
CAPRA-S. We found that when we added PCAT-14 to
CAPRA-S, it increased the receiver operating characteristic

area under the curve for 10-yr metastasis rates from 0.68
(CAPRA-S alone) to 0.70 (CAPRA-S + PCAT-14, p = 0.0185;
Supplementary Fig. 4).
3.3.

High PCAT-14 expression promotes a less aggressive

phenotype in vitro

To elucidate the mechanisms of PCAT-14 function, we
utilized our large patient cohort to identify genes with
correlated expression profiles to implicate PCAT-14 in
various biological processes (Supplementary Fig. 5). After
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Table 1 – Demographics in pooled cohort

Age (yr)
Missing
PSA <10
PSA 10–20
PSA >20
Missing
Gleason <7
Gleason =7
Gleason 8–10
Missing
Margins 
Margins +
Missing
SVI 
SVI +
Missing
ECE 
ECE +
Missing
LNI 
LNI +
Missing

High PCAT-14

Low PCAT-14

Total

63.8  7.07
0
250 (0.549)
98 (0.215)
95 (0.209)
12 (0.026)
62 (0.136)
268 (0.589)
125 (0.275)
0 (0)
220 (0.484)
235 (0.516)
0 (0)
310 (0.681)
145 (0.319)
0 (0)
224 (0.492)
230 (0.505)
1 (0.002)
411 (0.903)
43 (0.095)
1 (0.002)

64.2  6.91
0
243 (0.534)
106 (0.233)
96 (0.211)
10 (0.022)
37 (0.081)
196 (0.431)
221 (0.486)
1 (0.002)
190 (0.418)
265 (0.582)
0 (0)
292 (0.642)
163 (0.358)
0 (0)
205 (0.451)
248 (0.545)
2 (0.004)
390 (0.857)
65 (0.143)
0 (0)

64  6.99
0
493 (0.542)
204 (0.224)
191 (0.21)
22 (0.024)
99 (0.109)
464 (0.51)
346 (0.38)
1 (0.001)
410 (0.451)
500 (0.549)
0 (0)
602 (0.662)
308 (0.338)
0 (0)
429 (0.471)
478 (0.525)
3 (0.003)
801 (0.88)
108 (0.119)
1 (0.001)

p value
0.38
0.813

2.63E-10

0.0533

0.234

0.244

0.0323

ECE = extracapsular extension; LNI = lymph node invasion; PCAT14 = Prostate Cancer Associated Transcript-14; PSA = prostate-speciﬁc
antigen; SVI = seminal vesical involvement.

ranking all genes according to their correlation value, we
used Gene Set Enrichment Analysis [20] to search for
enrichment across the Molecular Signatures Database
[21]. We found an enrichment of Lys27 of histone
3 methylated target genes among the highest ranked
concepts, which were inversely correlated with PCAT-14
expression (Supplementary Fig. 5). Notably, EZH2 is overexpressed in metastatic prostate cancer, a marker of
aggressive disease, and is a critical component of the
polycomb repressive complex 2 that methylates Lys27 of
histone 3 to epigenetically silence target genes associated
with metastasis and poor patient outcome [22]. Furthermore, we observed numerous signatures associated with
tumor microenvironment that could also be indicative of
aggressive disease (Supplementary Fig. 5). Building upon
this, and to further support our clinical findings that low
PCAT-14 promotes aggressive disease, we evaluated what
effect changes in PCAT-14 expression had in vitro. Functional significance of PCAT-14 was assessed in aggressive
cell lines, IGR-Cap1 and PC3, with low endogenous
expression of PCAT-14 and well known to metastasize
[[2_TD$IF]23–25], by stably overexpressing the full length PCAT-14
clones.
Our in vitro findings support the clinical observations by
demonstrating increased PCAT-14 expression resulted in

Table 2 – Univariate and multivariate analysis
Univariate

DMFS

PCSS

OS

Age
PSA (int vs low)
PSA (high vs low)
Gleason (int vs low)
Gleason (high vs low)
SMS
SVI
ECE
LNI
PCAT14 (high vs low)
Age
PSA (int vs low)
PSA (high vs low)
Gleason (int vs low)
Gleason (high vs low)
SMS
SVI
ECE
LNI
PCAT14 (high vs low)
Age
PSA (int vs low)
PSA (high vs low)
Gleason (int vs low)
Gleason (high vs low)
SMS
SVI
ECE
LNI
PCAT14 (high vs low)

Multivariate

p value

HR (95% CI)

p value

0.76
0.452
0.00539
0.000805
2.70E-09
0.0616
6.92E-11
5.54E-08
5.65E-08
1.09E-06
0.638
0.386
0.038
0.0536
1.29E-06
0.000617
2.89E-13
1.08E-07
1.85E-12
6.54E-05
1.45E-05
0.751
0.011
0.00256
6.58E-12
0.000483
6.34E-09
9.76E-07
5.38E-08
0.00019

1 (0.99–1.02)
1.12 (0.84–1.49)
1.48 (1.12–1.94)
3.69 (1.72–7.93)
9.93 (4.66–21.16)
1.25 (0.99–1.57)
2.14 (1.7–2.69)
1.93 (1.52–2.45)
2.16 (1.63–2.85)
0.56 (0.44–0.71)
1.01 (0.98–1.03)
1.18 (0.81–1.74)
1.47 (1.02–2.11)
2.74 (0.98–7.62)
11.79 (4.34–32.01)
1.73 (1.26–2.37)
3.16 (2.32–4.3)
2.42 (1.75–3.36)
3.32 (2.38–4.64)
0.53 (0.39–0.72)
1.04 (1.02–1.06)
1.04 (0.8–1.36)
1.38 (1.08–1.78)
2.06 (1.29–3.29)
5.09 (3.2–8.11)
1.46 (1.18–1.8)
1.86 (1.51–2.29)
1.72 (1.38–2.14)
2.07 (1.59–2.69)
0.67 (0.54–0.83)

0.127
0.317
0.914
0.00651
1.62E-06
0.775
0.000659
0.0854
0.289
0.00201
0.472
0.108
0.0349
0.183
2.36E-04
0.0716
0.0000276
0.103
0.0215
0.0154
0.00541
0.0548
0.204
0.0321
2.86E-07
0.0397
0.00385
0.221
0.0605
0.056

HR (95% CI)
0.99
0.86
0.98
2.91
6.64
1.04
1.58
1.26
1.18
0.68
0.99
0.72
0.64
2.02
6.82
1.35
2.14
1.34
1.57
0.67
1.03
0.77
0.83
1.71
3.68
1.26
1.43
1.16
1.33
0.81

(0.97–1)
(0.64–1.16)
(0.72–1.34)
(1.35–6.29)
(3.06–14.39)
(0.81–1.32)
(1.21–2.05)
(0.97–1.64)
(0.87–1.62)
(0.53–0.87)
(0.97–1.02)
(0.49–1.07)
(0.43–0.97)
(0.72–5.66)
(2.45–18.96)
(0.97–1.87)
(1.5–3.05)
(0.94–1.92)
(1.07–2.29)
(0.48–0.93)
(1.01–1.05)
(0.58–1.01)
(0.62–1.11)
(1.05–2.79)
(2.24–6.05)
(1.01–1.57)
(1.12–1.83)
(0.91–1.48)
(0.99–1.79)
(0.65–1.01)

CI = conﬁdence interval; DMFS = distant metastasis-free survival; ECE = extracapsular extension; HR = hazard ratio; LNI = lymph node invasion; OS = overall
survival; PCAT-14 = Prostate Cancer Associated Transcript-14; PCSS = prostate cancer-speciﬁc survival; PSA = prostate-speciﬁc antigen; SMS = surgical margin
status; SVI = seminal vesical involvement.

262

EUROPEAN UROLOGY 71 (2017) 257–266

less aggressive phenotypes. In vitro experiments measuring
the mobility of cells overexpressing PCAT-14 show a
decreased migratory/invasive capacity of these cells relative
to the parental cell line with low PCAT-14 expression. PCAT14 overexpressing IGR-Cap1 cells and empty vector control
IGR-Cap1 cells were plated in serum-free media on a
transwell membrane and allowed to migrate in a modified
Boyden Chamber assay. After 24 h there was a significant
45% decrease in Clone 1 (p  0.00001) and 26% decrease in
Clone 2 (p  0.001) in the migration of PCAT-14 overexpressing cells compared with control cells (Fig. 3A). This
decrease in migration was also seen in PC3 PCAT-14
overexpressing cells (Fig. 3B). There was at least an 80%
decrease in migrated cells in both PC3 PCAT-14 overexpressing cell lines compared with the control cell line
(p  0.00001). Further, experiments were conducted with a
Matrigel-coated transwell to further confirm altering PCAT14 expression changes the aggressiveness of prostate cell
lines. Similar to migration assays, PCAT-14 overexpression
in both IGR-Cap1 and PC3 cells significantly diminished
cellular invasion compared with the control cell lines
(Supplementary Fig. 6). Similarly, silencing PCAT-14 with a
combination of small interfering RNAs (50% knockdown) in
22Rv1 cells with high endogenous expression resulted in a
137% (p  0.002) increase in migration relative to control
transfected cells (Supplementary Fig. 7). The changes in
migratory and invasive cellular behavior highlight that
changes in expression levels of PCAT-14 in prostate cancer
cause a less (high expression) or more (low expression)
aggressive phenotype. Cellular proliferation was also
monitored as an additional characterization of an aggressive
phenotype. IGR-Cap1 cells overexpressing two different
clones of PCAT-14 showed a 30% decrease in cell growth
relative to control cells at Day 2 (p = 0.001 and p = 0.00001).
The diminished growth in PCAT-14-expressing cells continued to Day 6 with a 16% and 37% change in Clone 1 and Clone
2 cell growth, respectively (Supplementary Fig. 8). Combined
these data indicate that increased PCAT-14 expression
diminishes oncogenic phenotypes in two well-studied
aggressive prostate cancer cell lines; further, silencing
PCAT-14 promotes an aggressive phenotype. Moreover,
these data support the strong clinical observations that
low PCAT-14 expression associates with aggressive disease.
3.4.

PCAT-14 association with androgen deprivation therapy

Through Gene Set Enrichment Analysis, we also found that
high PCAT-14 expression had a positive correlation with
genes involved in prostate cancer (Supplementary Fig. 5)
and androgen response (Fig. 4A). We also observed a
moderate correlation (0.49) between PCAT-14 expression
and androgen receptor transcriptional activity (Supplementary Fig. 9). Therefore, we investigated if PCAT-14 predicted
the response to therapies such as androgen deprivation
therapy (ADT) in the MCI and MCII cohorts. Of 780 patients,
236 underwent postoperative ADT within 1-yr of radical
prostatectomy. We found that the distant metastasis-free
survival prognostic differences between PCAT-14 high and
low expression are increased in patients treated with ADT

(p = 0.00082, HR = 0.5 [0.34–0.76]), and these differences
are attenuated in patients without ADT treatment
(p = 0.015, HR = 0.69 [0.51–0.93]) as shown in Figure 4B.
As our cohorts are all retrospective, which confounds
treatment by baseline risk, it is necessary to adjust for
clinical and pathologic variables and other treatments such
as radiotherapy. In our multivariate Cox model, which
accounts for these confounders, we found statistically
significant interaction terms for ADT and PCAT-14
(p = 0.029) indicating that PCAT-14 can potentially predict
the response to ADT after prostatectomy (Supplementary
Table 6). This is supported by PCAT-14 responsiveness to
testosterone and R1881 in VCaP cells (Supplementary Fig.
10). After androgen deprivation, VCaP cells were treated
with either 10 nM testosterone or 5 nM of R1881. There was
a six-fold and approximately four-fold increase in PCAT-14
expression with testosterone and R1881 treatment, respectively, relative to no treatment control. As a positive control,
there was also a robust increase in TMPRSS2 gene expression
with both drug treatments.
4.

Discussion

Our integrative analysis led us to discover a subset of
lncRNAs consistently altered across prostate cancer
patients suggesting their significance in prostate cancer
etiology. Notably, the Ren et al cohort [7] is comprised of
Chinese patients suggesting that these five lncRNAs are
altered independent of ethnicity. The importance of these
lncRNAs is exemplified by a recent study showing that
DRAIC plays a tumor-suppressive role, displays decreased
expression in prostate cancer cell progression from androgen-dependent to a castration-resistant state, and inhibits
cellular migration and invasion [9]. Less is known about the
remaining candidates that were only recently discovered
and reported to have altered expression during prostate
tumorigenesis [6,8] or are not yet associated with prostate
cancer (ie, LOC283177). However, PCAT-14 was the only
candidate that showed an inverse relationship with Gleason
score suggestive of its role in suppressing aggressive
disease, and therefore represents an ideal candidate to
investigate.
Herein, we show that PCAT-14 is overexpressed in
prostate tumors and that lower PCAT-14 expression
associates with three clinical endpoints (distant metastasis-free survival, prostate cancer specific survival, and
overall survival). Supporting our clinical findings, we have
provided experimental data highlighting the biological role
of PCAT-14 in prostate cancer. Firstly, using patient data we
were able to associate low PCAT-14 expression with
biological concepts associated with aggressive disease.
Secondly, we demonstrated that PCAT-14 suppresses
metastatic phenotypes in vitro and appears to lose
expression in metastatic samples. Stably overexpressing
PCAT-14 in both IGR-Cap1 and PC3 cells resulted in
significantly less cellular mobility relative to respective
control cell lines. Moreover, the opposite effect—a more
oncogenic phenotype—was observed in PCAT-14 silenced
22Rv1 cells. Taken together, this represents the first study
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Fig. 3 – Overexpression of Prostate Cancer Associated Transcript-14 (PCAT-14) diminishes cellular migration in vitro. (A) IGR-Cap1 or (B) PC3 cells were
plated for 24 h on a transwell membrane. Migrated cells (bottom of filter) were stained with 40 ,6-diamidino-2-phenylindole and quantified.
Quantitative reverse transcription polymerase chain reaction confirmed the overexpression of PCAT-14 in both cell lines relative to empty vector
control cell lines.
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Fig. 4 – Prostate Cancer Associated Transcript-14 (PCAT-14) is predictive of androgen deprivation therapy response. (A) Gene set enrichment analysis of
genes coexpressed with PCAT-14 revealed gene signatures associated with androgen response. Enrichment Score (ES) and false discovery rate (FDR) qvalue are shown within the gene set enrichment analysis plot. (B) Kaplan-Meier curves show that high PCAT-14 expression is differentially prognostic
of distant metastasis-free survival in patients treated with (left) and without (right) androgen deprivation therapy.
HR = hazard ratio.

highlighting the biological significance of PCAT-14 in
prostate cancer as well as the clinical significance of low
PCAT-14 expression for predicting outcome.
Notably, we observed that patients who received ADT
appeared to have a greater distant metastasis-free survival
prognostic difference between PCAT-14 high and low
expression in comparison to patients that did not receive
ADT. As these are retrospective studies, there are inherent
differences between patients that received treatment and
those that did not receive treatment. However, our

multivariate interaction analysis coupled with the in vitro
data demonstrating that PCAT-14 is androgen responsive
suggests that PCAT-14 warrants further study as a predictive
marker for ADT response.
5.

Conclusions

Overall, we discovered that PCAT-14 is commonly upregulated in primary tumors. Furthermore, low PCAT-14
expression promotes aggressive oncogenic phenotypes and

EUROPEAN UROLOGY 71 (2017) 257–266

is significantly prognostic for multiple clinical endpoints. In
addition to predicting metastatic disease, we found that
PCAT-14 may be able to predict ADT response highlighting
its potential use for improving patient management and
prognosis.
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model recapitulates mixed osteolytic/blastic bone lesions ob-

Tamayo P, Mesirov JP. Molecular signatures database (MSigDB)

served in metastatic prostate cancer. Neoplasia 2012;14:376–87,

3.0. Bioinformatics 2011;27:1739–40. http://dx.doi.org/10.1093/
bioinformatics/btr260.

2012 May;14.
[25] Chauchereau A, Al Nakouzi N, Gaudin C, et al. Stemness markers

[22] Yu J, Yu J, Rhodes DR, et al. A polycomb repression signature

characterize IGR-CaP1, a new cell line derived from primary epi-

in metastatic prostate cancer predicts cancer outcome. Cancer

thelial prostate cancer. Exp Cell Res 2011;317:262–75. http://dx.

Res 2007;67:10657–63. http://dx.doi.org/10.1158/0008-5472.

doi.org/10.1016/j.yexcr.2010.10.012.

CAN-07-2498.

